Skip to main
NKTX
NKTX logo

Nkarta, Inc. (NKTX) Stock Forecast & Price Target

Nkarta, Inc. (NKTX) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Nkarta Inc. is positioned favorably in the biopharmaceutical sector due to its innovative approach towards developing allogeneic, off-the-shelf engineered natural killer (NK) cell therapies for cancer treatment. The company's decision to reincorporate standardized lymphodepletion with fludarabine has significantly enhanced patient enrollment, indicating a strong operational momentum. Moreover, Nkarta's potential to capitalize on the biological and logistical advantages of NK cell therapies over traditional CAR-T therapies further supports a positive outlook from investors seeking exposure in this emerging therapeutic category.

Bears say

Nkarta Inc's financial outlook is negatively impacted by a significant decrease in research and development (R&D) spending, which was reported at $21 million, down 14% sequentially, raising concerns about the company’s ability to effectively fund its clinical programs. Additionally, the company's decision to amend its NKX019 treatment protocol and postpone preliminary year-end 2025 data disclosure has created uncertainty regarding the efficacy of its therapies, as management anticipates presenting more comprehensive results only at a FY26 medical conference. This delay, coupled with a substantial drop in selling, general, and administrative (SG&A) expenses, which fell 48% sequentially, suggests potential operational challenges and raises questions about the stability of Nkarta's growth trajectory in an increasingly competitive biopharmaceutical landscape.

Nkarta, Inc. (NKTX) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Nkarta, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Nkarta, Inc. (NKTX) Forecast

Analysts have given Nkarta, Inc. (NKTX) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Nkarta, Inc. (NKTX) has a Strong Buy consensus rating as of Dec 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Nkarta, Inc. (NKTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.